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Abstract.  
The large multimeric glycoprotein Von Willebrand factor (VWF) is best known for its role in 
haemostasis; however in recent years other functions of VWF have been identified, indicating that 
this protein is involved in multiple vascular processes. We recently described a new role for VWF in 
controlling angiogenesis, which may have significant clinical implications for patients with Von 
Willebrand disease (VWD), a genetic or acquired condition caused by the deficiency or dysfunction 
of VWF. VWD can be associated with angiodysplasia, a condition of degenerative blood vessels 
often present in the gastrointestinal tract, linked to dysregulated angiogenesis. Angiodysplasia can 
cause severe intractable bleeding, often refractory to conventional VWD treatments. In this review 
we summarise the evidence showing that VWF controls angiogenesis, and review the angiogenic 
pathways which have been implicated in this process. We discuss the possible mechanisms though 
which VWF regulates angiopoietin-2 (Ang-2) and integrin αvβ3, leading to signalling through 
vascular endothelial growth factor receptor-2 (VEGFR2), one of the most potent activators of 
angiogenesis. We also review the evidence that links VWF with angiodysplasia, and how the newly 
identified function of VWF in controlling angiogenesis may pave the way for the development of 
novel therapies for the treatment of angiodysplasia in congenital VWD and in acquired conditions 
such as Heyde syndrome.  
 
Introduction. The presence of vascular abnormalities 
in von Willebrand disease (VWD) was first described 
in the 1960s, when Armand J. Quick, one of the 
pioneers in the study of coagulation, reported the 
presence of telangectasias, defined as skin and mucous 
lesions consisting of dilated small blood vessels that 
tend to bleed (rev in
1
). Since then, several groups have 
reported the presence of vascular malformation in 
VWD patients in various localizations, including nail 
bed,
2
 skin, prostate and most frequently angiodysplasia 
of the gastrointestinal tract.
3
 These lesions can be 
responsible for severe, intractable bleeding which is 
often not responsive to VWF replacement therapy and 
thus represent a significant unmet clinical challenge. 
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Until recently, the pathological mechanism underlying 
vascular malformations in VWD was unexplained. 
However the recent discovery that von Willebrand 
factor (VWF) regulates blood vessel formation
4
 has 
shed new light on this syndrome and opened new 
avenues for the treatment of angiodysplasia. In this 
review we will summarise the process that led to this 
discovery, its implications for vascular biology and for 
the treatment of patients with VWD. 
 
The Cellular and Molecular Basis of Angiogenesis. 
Angiogenesis (the formation of new blood vessels from 
pre-existing ones) is a complex process which involves 
a cascade of events that require fine spatial and 
temporal coordination (rev in
5
). The initial pro-
angiogenic stimulus, often a growth factor produced in 
response to hypoxia, activates selected endothelial cells 
(EC) in the pre-existing vascular plexus to undergo 
changes in polarity and cytoskeletal remodelling, 
inducing migration towards the source of the pro-
angiogenic stimulus. These cells, named tip cells, 
maintain contact with the adjacent EC, called stalk 
cells, which acquire a different phenotype.
6
 Stalk cells 
proliferate to support the elongation of the new sprout. 
Eventually tip cells come into contact with other tip 
cells and through their thin finger-like protrusions 
(filopodia) engage in a cell fusion process, which is 
facilitated by tissue macrophages.
7
 Blood flow 
eventually completes canalisation of the new vascular 
sprout (rev in
8
). In order to become functional, blood 
vessels undergo stabilization and maturation, with 
active remodelling of the newly formed network, 
recruitment of mural cells and deposition of 
extracellular matrix.
9
 The process requires coordination 
between EC and other vascular cells, in particular 
pericytes and smooth muscle cells.  
Growth factors driving the initiation of angiogenesis: 
Vascular endothelial growth factor (VEGF). A large 
and growing number of molecules involved in 
regulating angiogenesis have been identified. Some are 
crucial for the initiation and/or progression of the 
process and their deficiency or dysregulation is 
incompatible with vascular development. Many other 
regulators, however, contribute to downstream steps in 
this complex process; their defect may give rise to 
dysfunctional vessels rather than complete disruption 
of the vasculature (rev in
5,10
). The best characterised 
pro-angiogenic endothelial growth factor is vascular 
endothelial growth factor (VEGF), a major regulator of 
vasculogenesis and physiological angiogenesis during 
embryogenesis, as well as physiological and 
pathological angiogenesis in the adult (rev in
5,11
). The 
VEGF system is also required for lymphangiogenesis 
(rev in
12
). VEGF-A is the best characterised member of 
a family which also includes VEGF-B, VEGF-C, 
VEGF-D and placental-derived growth factor. These 
bind to the VEGF receptors (R), of which 3 members 
(VEGF-R1, -R2 and -R3) have been identified. The 
complexity of the network is further enhanced by 
splicing and proteolytic cleavage of the ligands (rev 
in
13
). The main receptor for VEGF in the vascular 
endothelium is VEGFR2, which is critical for vascular 
development as well as adult angiogenesis (rev in
14
). 
VEGF exerts many effects on the vascular 
endothelium, including promoting proliferation, 
migration and survival as well as increased 
permeability (rev in 
14
). Binding of VEGF-A to VEGF-
R2 on EC stimulates dimerization of the receptor and 
autophosphorylation of specific intracellular tyrosine 
residues, leading to activation of intracellular signalling 
cascades, which lead to cell survival, permeability, 
migration and/or proliferation.
14
 In vivo, VEGF 
promotes angiogenesis; however overexpression of 
VEGF leads to the formation of fragile capillaries, with 
a disrupted structure, reminiscent of angiomas or 
angiodysplasia.
15,16
 
Growth factors controlling quiescence and vascular 
stability: the Angiopoietins and Tie-2 system. Whilst 
VEGF controls the early phases of the formation of a 
new blood vessel, the system most clearly involved in 
controlling the maturation and stability of new blood 
vessels is that of Angiopoietins and the Tie-2 receptor. 
Angiopoietin (Ang)-1 is produced by non-EC, such as 
pericytes and mural cells that contribute to vascular 
stability. Ang-1 binds to the tyrosine kinase receptor 
Tie-2, which is mainly expressed on EC; Ang-1 
signalling through Tie2 receptor promotes survival, 
quiescence and stability of blood vessels. Ang-1 also 
has anti-permeability and anti-inflammatory functions 
(rev in
17
). As ever, the picture is complicated by the 
fact that in some experimental models Ang-1 has been 
shown to promote cell migration and angiogenesis, in 
apparent conflict with its pro-quiescence properties. An 
interesting model has been put forward which proposes 
that differences in the localization of Tie-2 receptors on 
EC and their cell surface partners determines whether 
this signalling pathway supports quiescence or 
angiogenesis.
18,19
  
VEGF and Ang-1 play essential and complementary 
roles in vascular development and angiogenesis. 
During embryogenesis, VEGF is required for the 
formation of the initial vascular plexus, whilst Ang-1 is 
necessary for the remodelling of this early vascular 
network into mature blood vessels.
20
 A similar 
interplay between these two systems seems to take 
place during adult angiogenesis: both VEGF and Ang-1 
are able to promote angiogenesis in vivo;
21
 however 
VEGF causes vascular permeability and tissue oedema, 
whilst Ang-1 contributes to the stabilization and the 
maturation of growing blood vessels.
22,23
 Furthermore, 
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Ang-1 administration or overexpression in the dermal 
compartment can protect from the potentially lethal 
actions of VEGF as a consequence of uncontrolled 
plasma leakage.
24
 Co-expression of VEGF and Ang-1 
has recently been proposed as a strategy to generate 
more stable new vessels.
25
 
Another crucial regulator of the 
quiescence/angiogenesis balance is Ang-2. Ang-2 is an 
antagonistic ligand of Tie-2, which competitively 
inhibits binding of Ang-1, priming the endothelium for 
activation and vascular destabilisation. Ang-2 appears 
to act synergistically with VEGF to promote 
angiogenesis.
26
 Contrary to Ang-1, Ang-2 is 
synthesised by EC and stored in organelles called 
Weibel Palade Bodies (WPB), from where it can be 
rapidly released upon cellular activation.
27
 So whilst 
Ang-1 acts as an agonist of Tie-2, promoting structural 
integrity of blood vessels, Ang-2 acts as a naturally 
occurring antagonist, promoting vessel destabilisation 
and growth, as well as inflammation.
28
 Depending on 
the levels of other growth factors, such as VEGF-A, 
Ang-2 can also promote vessel regression (rev in
29
). 
The angiopoietin-Tie-2 system is also an area of 
intensive research for the development of modulatory 
drugs (rev in
30
).  
Extracellular cues and cell adhesion receptors 
controlling angiogenesis: integrin αvβ3. Molecular 
interactions mediated by several adhesion receptors 
and signalling complexes between cells need to be 
coordinated to maintain the integrity of the vessel and 
ultimately to stabilise the newly formed capillary. The 
extracellular environment is crucial for physiological 
development of the nascent sprout interaction; cell 
surface receptors of the integrin family mediate 
adhesion to and signalling by the extracellular matrix 
(ECM). Integrins are heterodimeric transmembrane 
proteins involved in the interaction of cells with their 
extracellular environment. In response to extracellular 
cues, integrins are able to transmit so called “outside-
in” signals to the cell leading to the activation of 
signalling cascades via various pathways including 
those of cellular adhesion and migration. The 
extracellular conformation of integrins can also be 
modulated by intracellular processes and transmit so 
called “inside-out” signals leading to changes in the 
way the receptor interacts with its extracellular matrix 
environment and modulation of protease activity (rev 
in
31
). One integrin receptor in particular, αvβ3, which is 
expressed on EC and is the best characterised 
endothelial receptor for VWF, has been shown to play 
a crucial role in angiogenesis and is a therapeutic target 
for cancer. The expression of αvβ3 is up-regulated in 
tumour associated blood vessels
32
 and drugs targeting 
αvβ3 have shown some success in clinical trials (rev 
in
33
); however its role appears quite complex, since 
deficiency of this integrin in the mouse has been linked 
with increased VEGFR2-dependent angiogenesis.
34
 
Interestingly αvβ3 can associate with VEGFR2 and 
crosstalk between these receptors can stimulate 
reciprocal activation (rev in
35
). Ang-1 and -2 have been 
shown to be able to regulate integrin mediated cell 
adhesion
36
 and Ang-2 can modulate αvβ3 integrin 
signalling.
19,37
  
 
Angiodysplasia: Vascular Lesions Linked to 
Abnormal Angiogenesis. Angiogenesis plays a crucial 
role during embryonic development and in specific 
processes during adulthood, such as wound healing and 
the menstrual cycle. Excessive or insufficient 
angiogenesis has been linked to a growing number of 
diseases (rev in
38
), and over the last few decades major 
progress in the understanding of the cellular and 
molecular basis of the process has been achieved. In 
parallel to the scientific progress, there has also been 
intense drug development activity in the search for 
inhibitors or activators. The area of vascular 
malformations, however, has received less attention 
and the links with the pathways controlling 
angiogenesis are poorly understood. The term 
angiodysplasia defines vascular malformation, also 
named ectasia, which affects submucosal veins, 
mucosal venules and capillaries. The abnormal 
vascular plexus is fragile and the architecture is 
disrupted, with possible arteriovenous 
communications. Angiodysplastic lesions are most 
commonly observed in the gastrointestinal (GI) tract 
and are the most common cause of occult GI bleeding 
in subjects over 65. A firm diagnosis of angiodysplasia 
may be difficult to achieve, partly because bleeding 
may be intermittent and partly because not all lesions 
are accessible to endoscopy. Although angiodysplasia 
is most frequently located in the proximal large colon 
(80% of lesions) which is visible by conventional 
methods, 15% of lesions are located in the small bowel 
and these may be either missed or require capsule 
endoscopy, which is not universally available. 
However, the use of capsule endoscopy has increased 
the diagnostic yield in patients with obscure GI 
bleeding to over 60% and as high as 93% in some 
series, depending on patient selection. This is a 
significant improvement over push enteroscopy, but in 
a small number of cases the diagnosis is one of 
exclusion based on the clinical picture of recurrent GI 
blood loss.
39
  
Despite the limited number of studies on the cellular 
and molecular basis of angiodysplasia, a link between 
angiodysplastic lesions and angiogenesis has been 
identified. The expression of the angiogenic growth 
factors VEGF and bFGF was found to be increased in 
samples of angiodysplastic tissue isolated from patients 
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presenting with angiodysplasia.
40,41
 Also, increased 
plasma levels of VEGF have been reported in patients 
with hereditary haemorrhagic telangectasia (HHT), 
who present with multiple angiodysplastic lesions,
42
 
and patients with genetic or acquired VWD
43
 (see 
below).  
 
Von Willebrand Factor as a new Regulator of 
Angiogenesis. Von Willebrand factor (VWF) is a large 
multimeric plasma glycoprotein well known for its 
crucial role in haemostasis, where it mediates platelet 
adhesion to the endothelium and the sub-endothelial 
matrix, and acts as a carrier for coagulation factor VIII 
(FVIII) in plasma. Deficiency or dysfunction of VWF 
causes von Willebrand disease (VWD), the most 
common genetic bleeding disorder in man.  
VWF is produced by EC and megakaryocytes; in 
EC, VWF can be constitutively secreted or stored in 
intracellular organelles called WPB, from where it can 
be secreted in response to various stimuli (rev in
44
). 
Although platelets contain VWF, plasma VWF levels 
have been shown to depend almost entirely on VWF 
from endothelial cells.
45
 The pathways of VWF 
synthesis, storage and secretion have been extensively 
investigated (rev in
46
). VWF drives the formation of 
WPB, which contain numerous proteins (rev in
47
). A 
proteomic approach has recently identified more WPB 
proteins.
48
 The list of known and newly discovered 
WPB molecules, shown in table 1, includes several 
molecules which play a role in angiogenesis.
47-50
 
Because VWF is essential for WPB formation, these 
proteins are dependent on VWF for their storage and 
regulated secretion (see below). 
In recent years, it has become evident that VWF 
plays multiple roles in the vasculature. VWF has been 
shown to control smooth muscle cell proliferation, 
vascular inflammation, cell death and tumour 
metastasis (rev in
51
). The large, complex structure of 
VWF protein supports multiple interactions with cell 
surface receptors and extracellular matrix proteins; in a 
recent review by Lenting et al,
51
 VWF has been 
described as a “molecular bus”, which can interact with 
20 other partners. The list of VWF interacting 
molecules is likely to expand, and with this the
Table 1. Known and potentially novel WPB content (based on Metcalf et al and van Breevoort et al. 47,48).  
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Figure 1. VWF and Angiopoietin-2 (Ang-2) co-localise in Weibel Palade Bodies (WPB) in Human Umbilical Vein Endothelial Cells 
(HUVEC).  WPB are visible as discrete rod-like structures inside the cell. See text for details. 
 
understanding of its multiple complex functions. 
Recently, our group demonstrated a novel function 
for VWF in the control of blood vessel formation.
4
 
Inhibition of VWF expression in EC in vitro was found 
to cause an increase in proliferation, migration and tube 
formation, all assays related to angiogenesis. 
Importantly, these findings were replicated in EC from 
patients with type 1 or type 2 VWD, which were 
isolated through a novel technique that uses circulating 
endothelial progenitors expanded in culture. These 
cells, called blood outgrowth endothelial cells or 
BOEC, have allowed for the first time access to EC 
from the patients, thus opening a new window on the 
cellular mechanisms controlling VWD. In line with 
these findings, both vascular development and adult 
angiogenesis were found to be increased in vivo, in 
VWF deficient mice. The mechanism of action of 
VWF in the control of angiogenesis involves enhanced 
signalling from the growth factor receptor VEGFR2, 
since an inhibitor to VEGFR2 restored in vitro 
migration
4
 and proliferation (Starke, Randi et al, in 
preparation) to normal. More recently, a similar result 
was observed following ablation of VEGFR2 
expression in EC in vitro by silencing RNA (Starke, 
Randi et al, in preparation).  
How does VWF control VEGFR2 signalling? The 
data indicate that this may occur through multiple 
mechanisms (Figure 2 and
4
). VWF was found to 
regulate two pathways, possibly linked, which may be 
controlling angiogenesis: an extracellular pathway 
involving integrin αvβ3 and an intracellular pathway 
involving Ang-2 storage in WPB. Both these pathways 
have been shown to influence VEGF signalling.
28,34
  
Integrin αvβ3 is the main endothelial receptor for 
VWF.
52
 αvβ3 is clearly implicated in angiogenesis, 
although there is some controversy as to its exact role. 
As discussed above, αvβ3 has been shown to both 
promote
53,54
 and repress angiogenesis.
34
 It is likely that 
the role of αvβ3 on the angiogenic process may depend 
on the cellular and extracellular context, interacting 
partners and/or the phase of angiogenesis (rev in
55
). 
Thus VWF may be modulating angiogenesis partly 
through interaction with αvβ3 on the endothelial cell 
surface. Interestingly, αvβ3 levels, function and 
trafficking were decreased in VWF-deficient EC,
4
 
suggesting that VWF may regulate αvβ3 activity in 
multiple ways.  
VWF may also control angiogenesis through an 
intracellular pathway which involves Ang-2. Ang-2 is 
normally stored WPB with VWF (Figure 1 and 
27
). In 
the absence of VWF, no WPB are formed; therefore 
Ang-2 may be constitutively released from the cells 
and presumably acts as a destabilizing, pro-angiogenic 
agent, as described above. Indeed our studies showed 
that in VWF-deficient EC in vitro, release of Ang-2 
was increased.
4
 More recent preliminary data from 
BOEC confirmed these observations, since Ang-2 
release from type 1 and type 3 VWD patients was 
found to be increased compared to control (Starke, 
Randi et al, in preparation). Interestingly, Ang-2 has 
been reported to stimulate the internalisation and 
degradation of αvβ337, which may link the two 
pathways controlled by VWF.  
Besides Ang-2, VWF interacts with or regulates the 
storage of several proteins which have been implicated 
in the control of angiogenesis, including interleukin-
8,
50
 galectin-1
56,57
 and galectin-3,
57,58
 connective tissue 
growth factor
59
 and insulin-like growth factor binding 
protein-7.
48,60
 Future studies will determine the relative 
importance of all these pathways in the control of 
vascular function and angiogenesis by VWF.  
These studies suggest that VWF controls stability 
and quiescence through an intracellular pathway, by 
directing the formation of WPB and hence the storage 
of Ang-2 (and possibly other angiogenic regulators), 
and extracellular pathway, by stabilizing αvβ3 on the  
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Figure 2. VWF controls angiogenesis through intracellular and 
extracellular pathways, involving Ang-2 and integrin v3 
respectively. These pathways converge to regulate angiogenesis 
through VEGF Receptor 2 signalling – see text for details.   
 
cell surface and regulating its levels and activity. In the 
absence of VWF, these pathways are perturbed and 
result in enhanced VEGF signalling and as a 
consequence enhanced proliferation, migration and 
angiogenesis (see model in Figure 2). Interestingly, 
preliminary data from BOEC from patients with type 1 
& 3 vs type 2 VWD suggest that different types may 
control angiogenesis through different mechanisms, 
since Ang-2 storage was normal in type 2 VWD 
patients (Starke, Randi et al, in preparation). 
 
Von Willebrand Disease, Angiogenesis and 
Angiodysplasia: Clinical Implications. Many 
investigators have described an association between 
VWD and angiodysplasia, particularly in the GI tract 
(rev in
1,61-63
); severe GI bleeding, which is often not 
resolved by conventional treatments, remains one of 
the most serious unmet clinical needs in VWD. Our 
data suggest that disturbed angiogenesis is linked to the 
development of angiodysplastic lesions in these 
patients. Angiodysplasia is most often observed in 
VWD patients lacking high molecular weight VWF 
multimers. The survey carried out by Fressinaud and 
Meyer reviewed histories from 4503 patients with 
VWD and found the incidence of angiodysplasia to 
vary with the VWD subtype. Angiodysplasia was most 
frequently associated with loss of VWF high molecular 
weight multimers (HMWM), being found in 2% of 
type 2 and 4.5% of type 3 respectively. In this study, 
no angiodysplasia in type 1 VWD was reported. 
Another study found a particular association with the 
VWD Type 2A mutation S1506L.
64
 Interestingly, 
vascular malformations and GI bleeding are also 
associated with acquired VWD, often in combination 
with aortic stenosis, in a triad that has been named 
Heyde syndrome (rev in
65
), which is also associated 
with loss of VWF HMWM. Heyde syndrome typically 
responds to aortic valve replacement with restoration of 
the normal multimer pattern and cessation of bleeding. 
For many years it was unclear whether this relationship 
was one of enhanced detection due to low levels of 
VWF or whether there was a causal relationship 
between VWF and GI bleeding. The finding that VWF 
can directly control vascular stability and angiogenesis 
provides the first mechanistic link and opens the way to 
possible novel therapeutic approaches to GI bleeding in 
VWD. So far, no evidence for a specific role of 
HMWM has been described in the molecular and 
cellular models in angiogenesis. However the 
molecular studies have identified both extracellular and 
intracellular pathways in the control of angiogenesis; 
thus it is possible that HMWM may affect the 
interaction of VWF with EC. Future studies will be 
required to determine the role of VWF multimers in 
angiogenesis.  
Initial treatment of GI blood loss in patients with 
VWD is logically carried out with VWF replacement 
therapy, which can reduce the incidence and severity of 
recurrent bleeding. However, the von Willebrand 
Disease Prophylaxis Network (VWD PN) study 
showed that prophylaxis was less successful at 
reducing GI blood loss than it was in reducing joint 
bleeding or menorrhagia.
66
 Moreover, it is well 
recognised that a subgroup of patients continue to have 
significant blood loss despite otherwise adequate 
replacement therapy. The failure of VWF replacement 
coupled with increased understanding of angiogenesis 
has prompted exploration of alternative therapies for 
this problem. Some success has been reported with 
thalidomide in angiodysplasia with or without VWD 
but this agent has a high incidence of side effects.
67,68
 
Most recently striking successes have been reported 
using atorvastatin which has been utilised for its anti-
angiogenic effect, but further trials will be required to 
determine whether this is reproducible.
69,70
 Moreover, 
the characterisation of the molecular pathways through 
which VWF regulates angiogenesis will provide novel 
therapeutic targets for the treatment of angiodysplastic 
GI bleeding.  
 
Conclusions. The finding that VWF regulates 
angiogenesis clearly has a number of important 
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implications. Firstly, it provides a novel link between 
VWD and angiodysplasia, which is likely to have 
therapeutic implications for the future. Secondly, it 
points the way to investigating the role of VWF in 
normal development and healing but also in 
pathological processes such as tumour growth, all of 
which depend on angiogenesis. We anticipate that 
these investigations will lead to novel agents to 
modulate angiogenesis for therapeutic benefit. A 
critical question for both of these problems will be 
determining the relative roles of intra- and extra-
cellular VWF in regulation of angiogenesis. We 
therefore remain some way from translation of these 
exciting findings into clinical practice. Experience to 
date suggests that replacement therapy does not always 
correct the defect in angiodysplasia and it is unlikely 
that simple infusion of VWF will be a panacea for 
abnormal vasculature.  
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